Regeneron Pharmaceuticals (REGN) Rating Lowered to Hold at BidaskClub

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, September 11th.

Several other brokerages have also issued reports on REGN. Barclays set a $290.00 target price on Regeneron Pharmaceuticals and gave the company a “sell” rating in a research report on Wednesday, May 23rd. SunTrust Banks reaffirmed a “hold” rating and set a $400.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 3rd. ValuEngine raised Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, September 6th. Canaccord Genuity lifted their price objective on Regeneron Pharmaceuticals from $304.00 to $390.00 and gave the stock a “hold” rating in a report on Friday, August 3rd. Finally, Cowen reissued a “hold” rating and issued a $385.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, August 16th. Two investment analysts have rated the stock with a sell rating, seventeen have given a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $411.10.

Shares of Regeneron Pharmaceuticals stock traded down $0.28 during trading hours on Tuesday, hitting $391.77. 452,619 shares of the company’s stock traded hands, compared to its average volume of 849,231. Regeneron Pharmaceuticals has a 12-month low of $281.89 and a 12-month high of $473.86. The firm has a market cap of $43.66 billion, a PE ratio of 29.21, a P/E/G ratio of 1.35 and a beta of 1.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.62 and a quick ratio of 2.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.60 by $0.85. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The firm had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same period last year, the firm posted $4.17 EPS. The business’s revenue was up 9.4% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 19.4 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 74,670 shares of the firm’s stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $367.22, for a total value of $27,420,317.40. Following the completion of the transaction, the chairman now owns 553,121 shares in the company, valued at approximately $203,117,093.62. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, August 2nd. The shares were sold at an average price of $380.00, for a total value of $760,000.00. Following the sale, the director now owns 14,000 shares of the company’s stock, valued at approximately $5,320,000. The disclosure for this sale can be found here. In the last 90 days, insiders sold 186,722 shares of company stock valued at $72,832,080. 12.42% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Wrapmanager Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 9.9% during the 2nd quarter. Wrapmanager Inc. now owns 1,440 shares of the biopharmaceutical company’s stock valued at $497,000 after buying an additional 130 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 4.7% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock valued at $1,085,000 after buying an additional 141 shares in the last quarter. Traynor Capital Management Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 9.8% during the 2nd quarter. Traynor Capital Management Inc. now owns 1,631 shares of the biopharmaceutical company’s stock valued at $572,000 after buying an additional 145 shares in the last quarter. Atria Investments LLC raised its holdings in shares of Regeneron Pharmaceuticals by 10.9% during the 2nd quarter. Atria Investments LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 147 shares in the last quarter. Finally, MUFG Securities EMEA plc raised its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the 2nd quarter. MUFG Securities EMEA plc now owns 9,031 shares of the biopharmaceutical company’s stock valued at $3,116,000 after buying an additional 152 shares in the last quarter. Hedge funds and other institutional investors own 66.90% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Understanding Average Daily Trade Volume

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply